Home
About Us
History
Mission & Values
Corporate Citizenship
Capabilities
Accreditations
People
Strategic Partnerships
Careers
Upcoming Events
Locations
News
Legal Notice & Agreement
Research Services & Partnering
Preclinical Testing Platforms
Translational Research
Clinical Trial Solutions
Research Software
Model Select®
Cell Line Select®
Lumin Bioinformatics Software
Resource Library
Blogs
Case Studies
Flow Cytometry Panels
Infographics
Model Spotlights
PDX Model Cohorts
Posters
Publications
Research Platforms
Software Platforms
Videos
Webinars
White Papers
Investors
Stock Information
Corporate Governance
SEC Filings
Contact Us
Transforming Drug Discovery
MENU
Champions Oncology Announces the Formation of Corellia AI, a Wholly Owned Biotech that Leverages Unique AI-Enabled Workflows for Novel Therapeutic Development
Champions Oncology Reports Quarterly Revenue of $12.8 Million
Champions Oncology Reports Record Quarterly Revenue of $14.3 Million
Champions Oncology Reports Record Quarterly Revenue of $13.7 Million
Champions Oncology Reports Quarterly Revenue of $12.9 Million
Champions Oncology Announces a Partnership with Cyclica to Develop Small Molecule Therapeutics
Champions Oncology Announces its Lumin Bioinformatics Platform Selected as a Finalist for the ‘Best in Show’ Competition at Bio-IT World Conference & Expo
Champions Oncology Reports Record Quarterly Revenue of $13.2 Million
Champions Oncology Announces a Partnership with GigaMune to Discover Novel Tumor-Reactive T Cell Receptors
Champions Oncology Announces a Partnership with Fannin Innovation to Jointly Develop Therapeutic Raptamer Drug Conjugates
Champions Oncology Announces a Partnership with Alloy Therapeutics to Develop Therapeutic Monoclonal Antibodies for Use in ADC Programs
Champions Oncology Reports Quarterly Revenue of $11.8 Million
Champions Oncology Expands Global Biomarker Capabilities with Opening of European Laboratory at OpenZone Life Sciences Campus
Champions Oncology Reports Record Quarterly Revenue of $11.3 Million
Champions Oncology Announces an Expanded Corporate Strategy to Include Drug Discovery and Development
Champions Oncology Reports Quarterly Revenue of $10.6 Million
Champions Oncology and BGI Americas Announce a Strategic Partnership to provide Mass Spectrometry Proteomics, Metabolomics, and multi-omic Data Analysis Solutions
Champions Oncology Reports Record Quarterly Revenue of $10.8 Million
Champions Oncology Announces Partnership with Code Ocean to Expand the Functionality of Lumin Bioinformatics
Champions Oncology Announces the Expansion of Lumin Bioinformatics: Now Featuring a Highly Valuable Set of Proteomic Data and Analytics
Champions Oncology Reports Record Quarterly Revenue of $10.1 Million
Champions Oncology Announces the Launch of Lumin Bioinformatics, Its New Oncology Data-Driven SaaS Program
Champions Oncology Expands Its Immuno-Oncology Research Offering by Launching a Unique Autologous Tumor Infiltrating Lymphocyte Ex Vivo Platform
Champions Oncology Reports Record Quarterly Revenue of $9.5 Million
Champions Oncology Reports Quarterly Revenue of $8.8 Million
Champions Oncology Reports Record Quarterly Revenue of $9.0 Million
The Children’s Cancer Therapy Development Institute is Collaborating with Champions Oncology and Jackson Laboratory to provide RACEact/PREA Pediatric Cancer Study Plan Services
Champions Oncology and PhenoVista Biosciences Announce a Strategic Partnership to provide Oncology Imaging-Based Phenotypic Assays for Preclinical Drug Development
Champions Oncology Partners with TransCure bioServices to Expand European Business and Operations
Champions Oncology Reports Record Quarterly Revenue of $6.2 Million
Champions Oncology Granted Full Accreditation by the AAALAC
Champions Oncology Reports Record Annual Revenue Exceeding $20M for Fiscal Year Ended April 30, 2018
Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies
Champions Oncology to Present at the 3rd Annual Disruptive Growth & Healthcare Conference on May 9th
Champions Oncology Adds Amy Wesa, Ph.D, as Director of Immuno-Oncology Research
Champions Oncology to Present at The MicroCap Conference on April 10th in New York City at the Essex House
Champions Oncology Reports Quarterly Revenue of $5.1 Million
Champions Oncology to Participate at the 30th Annual ROTH Conference
Motivated Patients with ROS1 Cancer Initiate Global Research Study
Champions Oncology Reports Record Quarterly Revenue of $5.2 Million
Champions Oncology announces $2 million award from the National Cancer Institute (NCI) to develop and evaluate prostate cancer PDX models
Champions Oncology announces publication highlighting clinical correlation between patient-derived xenograft (PDX) model responses and patient responses to oncology therapies
Champions Oncology Reports Record Quarterly Revenue of $5 Million
Champions Oncology Announces Strategic Collaboration with AstraZeneca to Develop Unique Cohorts of Patient-Derived Xenograft (PDX) Models
Champions Oncology Announces Research Collaboration with The Addario Lung Cancer Medical Institute to Develop Unique Cohort of Patient-Derived Xenograft (PDX) Models
Champions Oncology Reports 38% Revenue Growth
Champions Oncology Reports 40% Revenue Growth
Champions Oncology Announces Plan to Open New Lab Facility in Rockville, Maryland
Champions Oncology Announces New Collection of Patient-Derived Xenograft (PDX) Models Available for Translational Research
Champions Oncology Retains Hayden IR to Execute Comprehensive Investor Relations Program
Champions Oncology Reports 50% Revenue Growth, Accelerated Progress on Path to Profitability and Future Role Changes of the Senior Leadership
Champions Oncology Signs $2 million Contract
Champions Oncology Beats Revenue Guidance for Quarter; Reaffirms Full Year Guidance of 43 - 60% Revenue Growth
Champions Oncology Announces Revenue Up 26%, Projects 43% - 60% Growth For Current Fiscal Year
Champions Oncology to Announce Year-End 2016 Financial Results on Thursday, July 28, 2016
Champions Oncology Successfully Delivers First AML Study
Champions Oncology, Inc. Announces Closing of Public Offering of Common Stock
Champions Oncology, Inc. Announces Pricing of Public Offering of Common Stock
Champions Oncology Announces Addition to Board of Directors
Champions Oncology Reports Results for the Third Quarter Ended January 31, 2016
Champions To Present at the 28th Annual ROTH Capital Conference on March 16, 2016
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2016
Champions Oncology to Host Webinar on Patient-Derived Xenograft Program for Clinical Advancement
Champions Oncology Announces Initiation of Prospective Correlative Trial in Sarcoma
All posts
Latest Champions News